Celsius Therapeutics, a clinical-stage biotechnology company focused on developing precision medicines for inflammatory diseases, has been acquired by AbbVie for $250 million in cash. The acquisition enhances AbbVie’s existing portfolio in several key therapeutic areas such as immunology and oncology. Celsius Therapeutics’ cutting-edge approach involves the application of single-cell RNA sequencing to understand human biology at scale. Fast Track Initiative Inc., a venture capital firm specializing in early-stage life science startups, supported Celsius in its development journey. This acquisition reflects AbbVie’s strategy to integrate novel biotechnologies to address complex medical challenges.

Biotechnology, Pharmaceuticals, Venture Capital,United States, Japan

AbbVie Acquires Celsius Therapeutics